27 research outputs found
CARDIOVASCULAR RISK FACTORS AS POTENTIAL MARKERS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMERâS DISEASE
Background: Mild cognitive impairment (MCI) is an early stage of cognitive decline that has a significant risk of converting to
dementia. Cardiovascular pathology appears to have a major impact in cognitive decline, and it is clear that early identification and
correction of cardiovascular morbidity could have a major impact on cognitive functioning.
Subjects and methods: Our study was conducted in order to identify some cardiovascular risk factors among patients with
cognitive decline (MCI or Alzheimer disease-AD) and to find if there is any correlation with the degree of cognitive decline. We
evaluated the body mass index, total cholesterol, hypertension, history of smoking, alcohol consumption and diabetes mellitus in
patients with MCI and AD, compared with an age-matched control group.
Results: Regarding the body mass index, we observed a progressive decrease in patients with MCI and AD, in comparison with
the control group. Similar aspects were also observed in the case of cholesterol levels, only that post hoc analysis revealed no
significantly statistical differences between MCI and AD groups. The systolic blood pressure was increased in the patients with MCI
and AD. Also, as in the case of cholesterol levels, post hoc analysis revealed no significantly statistical differences between MCI and
AD groups. Pearsonâs correlation showed significant connections between the cardiovascular risk factors and the results of the
cognitive evaluation.
Conclusions: Our results constitute additional evidence that cardiovascular risk factors are involved in cognitive regression.
This finding could have an important impact on the management of dementia
Identification of Y-Box Binding Protein 1 As a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer Cells
Transcriptional signatures are an indispensible source of correlative information on disease-related molecular alterations on a genome-wide level. Numerous candidate genes involved in disease and in factors of predictive, as well as of prognostic, value have been deduced from such molecular portraits, e.g. in cancer. However, mechanistic insights into the regulatory principles governing global transcriptional changes are lagging behind extensive compilations of deregulated genes. To identify regulators of transcriptome alterations, we used an integrated approach combining transcriptional profiling of colorectal cancer cell lines treated with inhibitors targeting the receptor tyrosine kinase (RTK)/RAS/mitogen-activated protein kinase pathway, computational prediction of regulatory elements in promoters of co-regulated genes, chromatin-based and functional cellular assays. We identified commonly co-regulated, proliferation-associated target genes that respond to the MAPK pathway. We recognized E2F and NFY transcription factor binding sites as prevalent motifs in those pathway-responsive genes and confirmed the predicted regulatory role of Y-box binding protein 1 (YBX1) by reporter gene, gel shift, and chromatin immunoprecipitation assays. We also validated the MAPK-dependent gene signature in colorectal cancers and provided evidence for the association of YBX1 with poor prognosis in colorectal cancer patients. This suggests that MEK/ERK-dependent, YBX1-regulated target genes are involved in executing malignant properties
Validity and reliability of the Romanian version of the Hill-Bone compliance to high blood pressure therapy scale
Romania is considered a country with high cardiovascular risk, arterial hypertension and its complications accounting for about 60% of total deaths. The management of high blood pressure often involves a combination of both therapeutic regimens as well as lifestyle changes, to which patients have to be adherent. In order to assess patients adherence to professionalsâ recommendations, validated tools are needed. The aim of our study was to translate, culturally adapt and validate the Hill-Bone Compliance to High Blood Pressure Therapy Scale into Romanian. The study included 215 participants from Iasi, North-Eastern Romania. The internal consistency of the instrument was measured with Cronbachâs alpha coefficient, while the construct validity was determined using exploratory factor analysis and principal component extraction with promax rotation. Sampling adequacy and appropriateness of data for factor analysis was measured using Kaiser-Meyer-Olkin (KMO) statistics and Bartlettâs test of sphericity. Our statistical analysis revealed a Cronbachâs alpha coefficient of 0.733 (73.3%) and a Kaiser-Meyer-Olkin (KMO) Measure of Sampling Adequacy of 0.697. The chi square test demonstrated that the overall perfect adherence was not significantly associated with the number of medications taken per day variable (p = 0.721). The Romanian version of the Hill-Bone Compliance to High Blood Pressure Therapy Scale demonstrated suitability for its use in evaluating adherence in the intended population